SUMMARY

Our group is interested in both clinical and translational research with broad experience and grounded expertise in treating tumors since we are involved in tackling different neoplasms. We have participated in the most important trials with different drugs that, throughout 2013-2014, have demonstrated that they will change the prognosis of patients with prostate cancer. These new drugs include vaccines (Prostvac), Enzalutamide, and Radium-223 – all of which to-date show that they may improve the survival of our patients.

In other GU malignancies we are participating in clinical trials to evidence the utility of adjuvant treatment in renal cancer, or new drugs in second and third line treatment. In bladder cancer we are conducting new clinical studies that combine classical chemotherapy with novel targeted agents and second line treatments. We have collaborated in the development of new agents that are able to modulate the host immune response and combat cancer (PD-1 and PDL-1). In 2014 we have also participated in Phase I/II clinical trials to test new therapies and immunotherapeutics for bladder and prostate cancer. Our research into Central Nervous System (CNS) tumours has been further consolidated with the development of additional clinical trials and the creation of a Board comprised of experts in neurosurgery, radiology, radiotherapy, translational research, and medical oncology.

PUBLICATIONS